MR [Mindray Medical International] 6-K: Mindray Announces Second Quarter 2014 Financial Results Shenzhen,

[Mindray Announces Second Quarter 2014 Financial Results Shenzhen, China – August 11, 2014 – Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June 30, 2014. Highlights for Second Quarter 2014 - Net revenues increased 8.9% year-over-year to $334.5 million. International] []

MR [Mindray Medical International] SD: Section 1 — Conflict Minerals Disclosure Item 1.01

[Section 1 — Conflict Minerals Disclosure Item 1.01 ir.mindray.com Item 1.02 Item 2.01 Mindray Medical International Limited Alex Lung Chief Financial Officer] [In accordance with Rule 13p-1, Mindray undertook a reasonable country of origin inquiry (“RCOI”) to determine whether any of the conflict minerals necessary to the function or production of the products that Mindray manufactures originated in the Democratic Republic of Congo or an adjoining country (“Covered Country”). In conducting its due diligence, Mindray implemented the Conflict Mineral Reporting Template recommended]

MR [Mindray Medical International] SC 13G/A: (Original Filing)

[Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 1,706,700 Item 6: 0 Item 7: 1,787,000 Item 8: 0 Item 9: 1,787,000 Item 11: 2.091% Item 12: HC Cusip #Y6035S107 Item 1: Reporting Person - Edward C. Johnson 3d Item 5: 0 Item 6: 0 Item 7: 1,787,000 Item 8: 0 Item 9: 1,787,000 Item 11: 2.091%]

MR [Mindray Medical International] SC 13G/A: Item 1: Reporting Person – FMR LLC Item

[Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 1,706,700 Item 6: 0 Item 7: 1,787,000 Item 8: 0 Item 9: 1,787,000 Item 11: 2.091% Item 12: HC Cusip #Y6035S107 Item 1: Reporting Person - Edward C. Johnson 3d Item 5: 0 Item 6: 0 Item 7: 1,787,000 Item 8: 0 Item 9: 1,787,000 Item 11: 2.091%]

MR [Mindray Medical International] 6-K: (Original Filing)

[Mindray Announces First Quarter 2014 Financial Results SHENZHEN, China, May 5, 2014 — Mindray Medical International Limited (“Mindray”, NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the first quarter ended March 31, 2014. Highlights for First Quarter 2014 • Net revenues increased 9.4% year-over-year to $264.8 million. •] [EX-99.1 2 Mindray Medical International Limited]

MR [Mindray Medical International] 6-K: Mindray Announces First Quarter 2014 Financial Results SHENZHEN,

[Mindray Announces First Quarter 2014 Financial Results SHENZHEN, China, May 5, 2014 — Mindray Medical International Limited (“Mindray”, NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the first quarter ended March 31, 2014. Highlights for First Quarter 2014 • Net revenues increased 9.4% year-over-year to $264.8 million. •] [EX-99.1 2 Mindray Medical International Limited]

MR [Mindray Medical International] 20-F: INTRODUCTION 1 PART I. 3 ITEM 1. IDENTITY

[INTRODUCTION 1 PART I. 3 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 30 ITEM 4A. UNRESOLVED STAFF COMMENTS 53 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 53 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 83 ITEM 7.] [Name of Company Country of Shareholding Principal Activities Shenzhen Mindray Bio-Medical Electronics Co., Ltd. PRC MR Investments (HK) Limited: 88.918828% MR Holdings (HK) Limited: 11.081086% Non-controlling interest:0.000087%* Manufacturing and sales of medical equipment, research and development of related products and investment holding Shenzhen Mindray Investment & Development Co., Ltd. PRC Shenzhen Mindray Bio-Medical Electronics Co., Ltd.:99% Nanjing Mindray Bio-Medical Electronics] [CERTIFICATION I, Li Xiting, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [CERTIFICATION I, Cheng Minghe, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [CERTIFICATION I, Alex Lung, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [CERTIFICATION Li Xiting Director, President and Co-Chief Executive Officer Cheng Minghe Co-Chief Executive Officer and Chief Strategic Officer Alex Lung Chief Financial Officer EX-13.1 6 d646003dex131.htm EX-13.1] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (No. 333-178896) We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 Hong Kong April 28, 2014 EX-23.1 7 d646003dex231.htm EX-23.1]

MR [Mindray Medical International] SC 13G/A: (Original Filing)

[1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Baillie Gifford & Co (Scottish partnership) _______________________________________________________________________ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a).................................................................... (b).................................................................... _______________________________________________________________________ 3. SEC Use Only _______________________________________________________________________ 4. Citizenship or Place of Organization SCOTLAND UK _______________________________________________________________________ Number of 5. Sole Voting Power 7036961 Shares Bene ______________________________________________________]

MR [Mindray Medical International] SC 13G/A: 1. Names of Reporting Persons. I.R.S. Identification Nos.

[1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Baillie Gifford & Co (Scottish partnership) _______________________________________________________________________ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a).................................................................... (b).................................................................... _______________________________________________________________________ 3. SEC Use Only _______________________________________________________________________ 4. Citizenship or Place of Organization SCOTLAND UK _______________________________________________________________________ Number of 5. Sole Voting Power 7036961 Shares Bene ______________________________________________________]

MR [Mindray Medical International] 6-K: Mindray Announces ADS Dividend Record Date for March

[Mindray Announces ADS Dividend Record Date for March 2014 Dividend SHENZHEN, China, March 7, 2014 — Mindray Medical International Limited (“Mindray”, NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today that, in accordance with NYSE rules, holders of record of Mindray ADSs at the close of business on March 14, 2014 are entitled to the] [3 EX-99.1 4]

Skip to toolbar